who suggested in a research note that the add-on effect of efti on Keytruda is impressive. “Efti+pembro may provide a chemo-free option with similar (close enough) response rates as chemo ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.